Study: New drug candidate reduced brain inflammation, protected against cognitive decline in Alzheimer’s mouse model
An anti-inflammatory drug candidate, known as 3,6′-dithiopomalidomide (DP) and designed by researchers at the National Institute on Aging (NIA), protected lab mice against cognitive decline by reducing brain inflammation. An international research team led by the NIA scientists has published their findings in Alzheimer’s and Dementia: The Journal of the Alzheimer’s Association.
The study results provide new evidence that brain inflammation—which occurs decades before Alzheimer’s symptoms are noticeable—is a key neuropathological pathway of interest in efforts to find potential treatments for Alzheimer’s.
Source: Read Full Article